Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataMichael R. McClung, P. D. Delmas, S. Boonen et al.|Osteoporosis International|2012Cited by 31
Un nuevo enfoque para el desarrollo de las pautas de evaluación para osteoporosisJ. A. Kanis, Alan Tenenhouse, Dennis M. Black et al.|Unknown|2003Cited by 4
Rationale and design of the MOTION study (monthly oral therapy with ibandronate for osteoporosis intervention).Felicia Cosman, P. D. Delmas, Michael R. McClung et al.|Journal of Bone and Mineral Research|2005Cited by 2
The Management of Postmenopausal Osteoporosis: A Position Paper of the World Health Origination Collaborating Center on Public Health Aspects of Rheumatic DiseasesP. D. Delmas, Jean‐Yves Reginster, N. Khaltaev et al.|Open Repository and Bibliography (University of Liège)|2005Cited by 0
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Editorial commentCummings, C. Christiansen, J E Martin et al.|Unknown|2009Cited by 0